- Home
- IDYA vs DNLI Comparison
IDYA vs DNLI Comparison
Compare IDYA & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- DNLI
- Stock Information
- Founded
- IDYA 2015
- DNLI 2013
- Country
- IDYA United States
- DNLI United States
- Employees
- IDYA N/A
- DNLI N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IDYA Health Care
- DNLI Health Care
- Exchange
- IDYA Nasdaq
- DNLI Nasdaq
- Market Cap
- IDYA 2.3B
- DNLI 2.4B
- IPO Year
- IDYA 2019
- DNLI 2017
- Fundamental
- Price
- IDYA $31.60
- DNLI $16.38
- Analyst Decision
- IDYA Buy
- DNLI Strong Buy
- Analyst Count
- IDYA 17
- DNLI 14
- Target Price
- IDYA $48.20
- DNLI $33.50
- AVG Volume (30 Days)
- IDYA 1.3M
- DNLI 1.6M
- Earning Date
- IDYA 11-04-2025
- DNLI 11-03-2025
- Dividend Yield
- IDYA N/A
- DNLI N/A
- EPS Growth
- IDYA N/A
- DNLI N/A
- EPS
- IDYA N/A
- DNLI N/A
- Revenue
- IDYA $7,000,000.00
- DNLI N/A
- Revenue This Year
- IDYA $90.17
- DNLI N/A
- Revenue Next Year
- IDYA $219.42
- DNLI $94,232.03
- P/E Ratio
- IDYA N/A
- DNLI N/A
- Revenue Growth
- IDYA N/A
- DNLI N/A
- 52 Week Low
- IDYA $13.45
- DNLI $10.57
- 52 Week High
- IDYA $33.64
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- IDYA 63.75
- DNLI 56.26
- Support Level
- IDYA $28.17
- DNLI $15.53
- Resistance Level
- IDYA $33.64
- DNLI $17.02
- Average True Range (ATR)
- IDYA 1.70
- DNLI 0.86
- MACD
- IDYA 0.33
- DNLI -0.02
- Stochastic Oscillator
- IDYA 72.58
- DNLI 63.78
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.